Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Community Healthcare Quality Standards to Prevent Acute Kidney Injury and its Consequences.

Silver SA, Nadim MK, O'Donoghue DJ, Wilson FP, Kellum JA, Mehta RL, Ronco C, Kashani K, Rosner MH, Haase M, Lewington AJ.

Am J Med. 2019 Dec 9. pii: S0002-9343(19)31081-2. doi: 10.1016/j.amjmed.2019.10.038. [Epub ahead of print] Review.

PMID:
31830434
2.

Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis".

Garcia-Tsao G, Angeli P, Nadim MK, Parikh CR.

J Hepatol. 2019 Dec 3. pii: S0168-8278(19)30673-7. doi: 10.1016/j.jhep.2019.11.005. [Epub ahead of print] No abstract available.

PMID:
31810532
3.

MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.

Asrani SK, Jennings LW, Kim WR, Kamath P, Levitsky J, Nadim MK, Testa G, Leise M, Trotter JF, Klintmalm G.

Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932. [Epub ahead of print]

PMID:
31523825
4.

News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.

Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR.

J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11. Review.

PMID:
31302175
5.

Quality Improvement Goals for Acute Kidney Injury.

Kashani K, Rosner MH, Haase M, Lewington AJP, O'Donoghue DJ, Wilson FP, Nadim MK, Silver SA, Zarbock A, Ostermann M, Mehta RL, Kane-Gill SL, Ding X, Pickkers P, Bihorac A, Siew ED, Barreto EF, Macedo E, Kellum JA, Palevsky PM, Tolwani AJ, Ronco C, Juncos LA, Rewa OG, Bagshaw SM, Mottes TA, Koyner JL, Liu KD, Forni LG, Heung M, Wu VC.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):941-953. doi: 10.2215/CJN.01250119. Epub 2019 May 17.

PMID:
31101671
6.

Hepatorenal Syndrome.

Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK.

Clin J Am Soc Nephrol. 2019 May 7;14(5):774-781. doi: 10.2215/CJN.12451018. Epub 2019 Apr 17.

PMID:
30996046
7.

Acute kidney injury in cirrhosis: implications for liver transplantation.

MacDonald AJ, Nadim MK, Durand F, Karvellas CJ.

Curr Opin Crit Care. 2019 Apr;25(2):171-178. doi: 10.1097/MCC.0000000000000590.

PMID:
30676329
8.

A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction.

Asrani SK, Jennings LW, Trotter JF, Levitsky J, Nadim MK, Kim WR, Gonzalez SA, Fischbach B, Bahirwani R, Emmett M, Klintmalm G.

Hepatology. 2019 Mar;69(3):1219-1230. doi: 10.1002/hep.30321. Epub 2019 Feb 20.

PMID:
30338870
9.

Author Correction: Hepatorenal syndrome.

Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS.

Nat Rev Dis Primers. 2018 Oct 15;4(1):33. doi: 10.1038/s41572-018-0035-2.

PMID:
30323303
10.

Hepatorenal syndrome.

Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS.

Nat Rev Dis Primers. 2018 Sep 13;4(1):23. doi: 10.1038/s41572-018-0022-7. Review. Erratum in: Nat Rev Dis Primers. 2018 Oct 15;4(1):33.

PMID:
30213943
11.

Cardiac and Vascular Surgery-Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group.

Nadim MK, Forni LG, Bihorac A, Hobson C, Koyner JL, Shaw A, Arnaoutakis GJ, Ding X, Engelman DT, Gasparovic H, Gasparovic V, Herzog CA, Kashani K, Katz N, Liu KD, Mehta RL, Ostermann M, Pannu N, Pickkers P, Price S, Ricci Z, Rich JB, Sajja LR, Weaver FA, Zarbock A, Ronco C, Kellum JA.

J Am Heart Assoc. 2018 Jun 1;7(11). pii: e008834. doi: 10.1161/JAHA.118.008834. Review. No abstract available.

12.

Acute Kidney Injury After Liver Transplantation.

Durand F, Francoz C, Asrani SK, Khemichian S, Pham TA, Sung RS, Genyk YS, Nadim MK.

Transplantation. 2018 Oct;102(10):1636-1649. doi: 10.1097/TP.0000000000002305.

PMID:
29847502
13.

Renal dysfunction and cirrhosis.

Durand F, Olson JC, Nadim MK.

Curr Opin Crit Care. 2017 Dec;23(6):457-462. doi: 10.1097/MCC.0000000000000457. Review.

PMID:
29023314
14.

Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.

Nadim MK, DiNorcia J, Ji L, Groshen S, Levitsky J, Sung RS, Kim WR, Andreoni K, Mulligan D, Genyk YS.

J Hepatol. 2017 Sep;67(3):517-525. doi: 10.1016/j.jhep.2017.04.022. Epub 2017 May 5.

PMID:
28483678
15.

Intensive care unit management: Renal replacement therapy, ventilator management, volume assessment, and optimal management of hypotension.

Nadim MK, Olson JC.

Clin Liver Dis (Hoboken). 2017 Mar 30;9(3):69-72. doi: 10.1002/cld.621. eCollection 2017 Mar. Review. No abstract available.

16.

Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.

de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA; DEBuT-HT and Rheos Trial Investigators.

Hypertension. 2017 May;69(5):836-843. doi: 10.1161/HYPERTENSIONAHA.117.09086. Epub 2017 Mar 20.

PMID:
28320856
17.

What endpoints should be used for clinical studies in acute kidney injury?

Kellum JA, Zarbock A, Nadim MK.

Intensive Care Med. 2017 Jun;43(6):901-903. doi: 10.1007/s00134-017-4732-1. Epub 2017 Mar 2. No abstract available.

PMID:
28255614
18.

Perioperative Renal Replacement Therapy in Liver Transplantation.

DiNorcia J, Meouchy J, Genyk YS, Nadim MK.

Int Anesthesiol Clin. 2017 Spring;55(2):81-91. doi: 10.1097/AIA.0000000000000136. Review. No abstract available.

PMID:
28225534
19.

An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.

Wachter R, Halbach M, Bakris GL, Bisognano JD, Haller H, Beige J, Kroon AA, Nadim MK, Lovett EG, Schafer JE, de Leeuw PW.

J Am Soc Hypertens. 2017 Feb;11(2):81-91. doi: 10.1016/j.jash.2016.12.003. Epub 2016 Dec 16.

20.

Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".

Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS.

J Hepatol. 2016 May 27. pii: S0168-8278(16)30185-4. doi: 10.1016/j.jhep.2016.05.001. [Epub ahead of print] No abstract available.

PMID:
27241199
21.

Kidney biomarkers in cirrhosis.

Francoz C, Nadim MK, Durand F.

J Hepatol. 2016 Oct;65(4):809-824. doi: 10.1016/j.jhep.2016.05.025. Epub 2016 May 26. Review.

PMID:
27238754
22.

Management of Acute-on-Chronic Liver Failure.

Durand F, Nadim MK.

Semin Liver Dis. 2016 May;36(2):141-52. doi: 10.1055/s-0036-1583198. Epub 2016 May 12. Review.

PMID:
27172356
23.

Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.

O'Leary JG, Levitsky J, Wong F, Nadim MK, Charlton M, Kim WR.

Am J Transplant. 2016 Sep;16(9):2516-31. doi: 10.1111/ajt.13790. Epub 2016 May 13. Review.

24.

Management of the critically ill patient with cirrhosis: A multidisciplinary perspective.

Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS.

J Hepatol. 2016 Mar;64(3):717-35. doi: 10.1016/j.jhep.2015.10.019. Epub 2015 Oct 28. Review. No abstract available.

25.

Pathogenesis of Hepatorenal Syndrome: Implications for Therapy.

Durand F, Graupera I, Ginès P, Olson JC, Nadim MK.

Am J Kidney Dis. 2016 Feb;67(2):318-28. doi: 10.1053/j.ajkd.2015.09.013. Epub 2015 Oct 21. Review.

PMID:
26500178
26.

Acute Kidney Injury in Cirrhosis.

Karvellas CJ, Durand F, Nadim MK.

Crit Care Clin. 2015 Oct;31(4):737-50. doi: 10.1016/j.ccc.2015.06.009. Epub 2015 Aug 5. Review.

PMID:
26410141
27.

Hepatorenal Disorders.

Al-Khafaji A, Nadim MK, Kellum JA.

Chest. 2015 Aug;148(2):550-558. doi: 10.1378/chest.14-1925. Review.

PMID:
25811649
28.

Renal Denervation in Heart Failure.

Fong MW, Shavelle D, Weaver FA, Nadim MK.

Curr Hypertens Rep. 2015 Mar;17(3):17. doi: 10.1007/s11906-014-0528-7. Review.

PMID:
25754320
29.

Resistant hypertension: medical management and alternative therapies.

Ghofrani H, Weaver FA, Nadim MK.

Cardiol Clin. 2015 Feb;33(1):75-87. doi: 10.1016/j.ccl.2014.09.003. Review.

PMID:
25439332
30.

Intraoperative hemodialysis during liver transplantation: a decade of experience.

Nadim MK, Annanthapanyasut W, Matsuoka L, Appachu K, Boyajian M, Ji L, Sedra A, Genyk YS.

Liver Transpl. 2014 Jul;20(7):756-64. doi: 10.1002/lt.23867.

31.

Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations.

Francoz C, Nadim MK, Baron A, Prié D, Antoine C, Belghiti J, Valla D, Moreau R, Durand F.

Hepatology. 2014 Apr;59(4):1514-21. doi: 10.1002/hep.26704. Epub 2014 Mar 3.

PMID:
24037821
32.

Simultaneous liver-kidney transplantation summit: current state and future directions.

Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, Feng S, Friedewald JJ, Hong JC, Kellum JA, Kim WR, Lake JR, Melton LB, Pomfret EA, Saab S, Genyk YS.

Am J Transplant. 2012 Nov;12(11):2901-8. doi: 10.1111/j.1600-6143.2012.04190.x. Epub 2012 Jul 23. Review.

33.

Simultaneous liver-kidney transplantation: a survey of US transplant centers.

Nadim MK, Davis CL, Sung R, Kellum JA, Genyk YS.

Am J Transplant. 2012 Nov;12(11):3119-27. doi: 10.1111/j.1600-6143.2012.04176.x. Epub 2012 Jul 3.

34.

Living donor liver transplantation for hepatorenal syndrome: to do or not to do? That is the question.

Nadim MK, Sung RS.

Liver Transpl. 2012 Oct;18(10):1138-9. doi: 10.1002/lt.23498. No abstract available.

35.

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD.

J Am Soc Hypertens. 2012 Mar-Apr;6(2):152-8. doi: 10.1016/j.jash.2012.01.003. Epub 2012 Feb 15.

PMID:
22341199
36.

Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS; ADQI Workgroup.

Crit Care. 2012 Feb 9;16(1):R23. doi: 10.1186/cc11188. Review.

37.

Medical management of hepatorenal syndrome.

Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK.

Nephrol Dial Transplant. 2012 Jan;27(1):34-41. doi: 10.1093/ndt/gfr736. Review.

PMID:
22287700
38.

Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome.

Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R.

Liver Transpl. 2012 May;18(5):539-48. doi: 10.1002/lt.23384.

39.

Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA.

J Am Coll Cardiol. 2011 Aug 9;58(7):765-73. doi: 10.1016/j.jacc.2011.06.008.

40.

Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis.

Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V.

Gut. 2011 May;60(5):702-9. doi: 10.1136/gut.2010.236133. Epub 2011 Feb 15.

PMID:
21325171
41.

An overview of drug-induced acute kidney injury.

Pannu N, Nadim MK.

Crit Care Med. 2008 Apr;36(4 Suppl):S216-23. doi: 10.1097/CCM.0b013e318168e375. Review.

PMID:
18382197
42.

Fluids for prevention and management of acute kidney injury.

Kellum JA, Cerda J, Kaplan LJ, Nadim MK, Palevsky PM.

Int J Artif Organs. 2008 Feb;31(2):96-110.

PMID:
18311727
43.

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

Campese VM, Nadim MK, Epstein M.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S11-7. Review.

44.

Antihypertensive drugs and the kidney.

Nadim MK, Dua R, Campese VM.

Curr Cardiol Rep. 2004 Nov;6(6):403-8. Review.

PMID:
15485598
45.

Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression.

Taal MW, Omer SA, Nadim MK, Mackenzie HS.

Curr Opin Nephrol Hypertens. 2000 Jul;9(4):323-31. Review.

PMID:
10926167
46.

Glomerular normalcy and pathosis: a "fin de millénaire" perspective.

Nadim MK, Brenner BM.

J Nephrol. 1999 Jul-Aug;12 Suppl 2:S16-28. Review. No abstract available.

PMID:
10688399
47.

Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.

Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW.

J Am Soc Nephrol. 1999 Apr;10 Suppl 12:S283-6. Review.

PMID:
10201884

Supplemental Content

Loading ...
Support Center